inclusion criteria: * patient with sars-cov-2 infection as determined by real time polymerase chain reaction (rt- pcr) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. onset of symptoms of covid-19 must be 14 or fewer days prior to randomization. patient with a second sars-cov-2 episode after resolution of the initial infection may be enrolled if the initial infection had clearly resolved, re-infection is reconfirmed by rt-pcr and all other eligibility criteria are met * hospitalized patient who requires oxygen supplementation via either low-flow oxygen device (such as nasal cannula or face mask), high flow oxygen therapy (including high-flow nasal cannula), or non invasive ventilation to maintain peripheral oxygen saturation of at least 94%. the patient must have had such an oxygen requirement for 2 days or fewer at the time of screening, and the oxygen requirement must be non-improving (worsening or stable) in the investigator's judgement at the time of screening and randomization * female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study * ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so * patient is willing and able to comply with all required study visits and follow up required by the protocol * patient must agree not to enroll in another study of an investigational agent prior to completion of day 60 of study

inclusion criteria: * patient with sars-cov-2 infection as determined by real time polymerase chain reaction (rt- pcr) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. onset of symptoms of covid-19 must be 14 or fewer days prior to randomization. patient with a second sars-cov-2 episode after resolution of the initial infection may be enrolled if the initial infection had clearly resolved, re-infection is reconfirmed by rt-pcr and all other eligibility criteria are met * hospitalized patient who requires oxygen supplementation via either low-flow oxygen device (such as nasal cannula or face mask), high flow oxygen therapy (including high-flow nasal cannula), or non invasive ventilation to maintain peripheral oxygen saturation of at least 94%. the patient must have had such an oxygen requirement for 2 days or fewer at the time of screening, and the oxygen requirement must be non-improving (worsening or stable) in the investigator's judgement at the time of screening and randomization * female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study * ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so * patient is willing and able to comply with all required study visits and follow up required by the protocol * patient must agree not to enroll in another study of an investigational agent prior to completion of day 60 of study

inclusion criteria: patient with sars-cov-2 infection as determined by real time polymerase chain reaction (rt- pcr) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. onset of symptoms of covid-19 must be 14 or fewer days prior to randomization. patient with a second sars-cov-2 episode after resolution of the initial infection may be enrolled if the initial infection had clearly resolved, re-infection is reconfirmed by rt-pcr and all other eligibility criteria are met hospitalized patient who requires oxygen supplementation via either low-flow oxygen device (such as nasal cannula or face mask), high flow oxygen therapy (including high-flow nasal cannula), or non invasive ventilation to maintain peripheral oxygen saturation of at least 94%. the patient must have had such an oxygen requirement for 2 days or fewer at the time of screening, and the oxygen requirement must be non-improving (worsening or stable) in the investigator's judgement at the time of screening and randomization female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so patient is willing and able to comply with all required study visits and follow up required by the protocol patient must agree not to enroll in another study of an investigational agent prior to completion of day 60 of study

inclusion criteria: patient with sars-cov-2 infection as determined by real time polymerase chain reaction (rt- pcr) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. onset of symptoms of covid-19 must be 14 or fewer days prior to randomization. patient with a second sars-cov-2 episode after resolution of the initial infection may be enrolled if the initial infection had clearly resolved, re-infection is reconfirmed by rt-pcr and all other eligibility criteria are met hospitalized patient who requires oxygen supplementation via either low-flow oxygen device (such as nasal cannula or face mask), high flow oxygen therapy (including high-flow nasal cannula), or non invasive ventilation to maintain peripheral oxygen saturation of at least 94%. the patient must have had such an oxygen requirement for 2 days or fewer at the time of screening, and the oxygen requirement must be non-improving (worsening or stable) in the investigator's judgement at the time of screening and randomization female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so patient is willing and able to comply with all required study visits and follow up required by the protocol patient must agree not to enroll in another study of an investigational agent prior to completion of day 60 of study

inclusion criteria: - patient with sars-cov-2 infection as determined by real time polymerase chain reaction (rt- pcr) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. patient with a second sars-cov-2 episode after resolution of the initial infection may be enrolled if the infection is reconfirmed by rt-pcr and all other eligibility criteria are met. patient hospitalized, who are requiring supplemental oxygen via nasal cannula, non-invasive ventilation or high-flow oxygen to maintain peripheral oxygen saturation of at least 92% at time of screening - female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study - ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so - patient is willing and able to comply with all required study visits and follow up required by the protocol - patient must agree not to enroll in another study of an investigational agent prior to completion of day 60 of study

inclusion criteria: - patient with sars-cov-2 infection as determined by real time polymerase chain reaction (rt- pcr) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. patient with a second sars-cov-2 episode after resolution of the initial infection may be enrolled if the infection is reconfirmed by rt-pcr and all other eligibility criteria are met. patient hospitalized, who are requiring supplemental oxygen via nasal cannula, non-invasive ventilation or high-flow oxygen to maintain peripheral oxygen saturation of at least 92% at time of screening - female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study - ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so - patient is willing and able to comply with all required study visits and follow up required by the protocol - patient must agree not to enroll in another study of an investigational agent prior to completion of day 60 of study